FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051238437> ?p ?o ?g. }

• W2051238437 endingPage "235" @default.
• W2051238437 startingPage "225" @default.
• W2051238437 abstract "Objective. Colorectal cancer is the second largest cause of death from malignant disease in Western countries. Although surgical resection is the preferred treatment in early disease, chemotherapy has an important role to play both as an adjunct to surgery and in the palliation of advanced disease. For many years 5-fluorouracil (5-FU) has been the only cyto toxic drug with significant activity in this condition and, recently, considerable effort has been directed toward enhancing its activity and finding better, alternative agents. Recently, raltitrexed (Tomudex; Zeneca Pharmaceuticals), the first of a new class of cytotoxic drugs, the selective, direct, thymidylate synthase inhibitors, received its first regulatory ap proval for the first-line treatment of advanced colo rectal cancer. The purpose of this review is to con sider the efficacy, toxicity, and resource implications of using this new antineoplastic agent, alongside developments that have been made in the more effective use of fluoropyrimidines, and the place of drug treatment in the management of colorectal cancer. Data Sources. A variety of sources were used, including manual and on-line (Medline and Pharm- line) literature searching. Approved and other drug names were used as primary search terms, linked with colorectal cancer where limitation was required. The medical information department of Zeneca Pharma ceuticals also was used where appropriate. Study Selection. Particular attention was di rected to randomized clinical trials, but nonrandom ized and preclinical studies were considered where appropriate. Conclusions. Although colorectal cancer is in herently resistant to cytotoxic chemotherapy, such treatment now has an established role as an adjunct to surgery and in the palliation of advanced disease. The optimum 5-FU- based regimen has yet to be estab lished with certainty, although in advanced disease a four-times-weekly, 5-day regimen of 5-FU and low- dose folinic acid is probably the best of those fully evaluated to date. Raltitrexed seems to be as effective as this combination while having definite advantages in terms of toxicity and the resources required for its preparation and administration, although it remains to be seen to what extent these and other resource benefits will be offset by its higher cost and how its efficacy and tolerability will compare with other 5-FU- based regimens in ongoing clinical trials." @default.
• W2051238437 created "2016-06-24" @default.
• W2051238437 creator A5035197851 @default.
• W2051238437 date "1996-12-01" @default.
• W2051238437 modified "2023-09-25" @default.
• W2051238437 title "Raltitrexed and the treatment of advanced colorectal cancer" @default.
• W2051238437 cites W1769344090 @default.
• W2051238437 cites W178877402 @default.
• W2051238437 cites W1844072307 @default.
• W2051238437 cites W1847455118 @default.
• W2051238437 cites W1902766545 @default.
• W2051238437 cites W192923250 @default.
• W2051238437 cites W1930945683 @default.
• W2051238437 cites W1962875322 @default.
• W2051238437 cites W1969825132 @default.
• W2051238437 cites W1971378447 @default.
• W2051238437 cites W1971874283 @default.
• W2051238437 cites W1976941903 @default.
• W2051238437 cites W1986924507 @default.
• W2051238437 cites W1988135096 @default.
• W2051238437 cites W1997977249 @default.
• W2051238437 cites W2007615142 @default.
• W2051238437 cites W2008821649 @default.
• W2051238437 cites W2016791396 @default.
• W2051238437 cites W2025488028 @default.
• W2051238437 cites W2044224410 @default.
• W2051238437 cites W2047510518 @default.
• W2051238437 cites W2048710533 @default.
• W2051238437 cites W2055109849 @default.
• W2051238437 cites W2055568666 @default.
• W2051238437 cites W2087895893 @default.
• W2051238437 cites W2095355415 @default.
• W2051238437 cites W2106482770 @default.
• W2051238437 cites W2122364701 @default.
• W2051238437 cites W2128813634 @default.
• W2051238437 cites W2132039541 @default.
• W2051238437 cites W2139040913 @default.
• W2051238437 cites W2150985317 @default.
• W2051238437 cites W2159848047 @default.
• W2051238437 cites W2166199856 @default.
• W2051238437 cites W2227373247 @default.
• W2051238437 cites W2234894755 @default.
• W2051238437 cites W2253033732 @default.
• W2051238437 cites W2255487108 @default.
• W2051238437 cites W2275576700 @default.
• W2051238437 cites W2313857605 @default.
• W2051238437 cites W2330504627 @default.
• W2051238437 cites W2331042177 @default.
• W2051238437 cites W2341601510 @default.
• W2051238437 cites W2408405914 @default.
• W2051238437 cites W2412592725 @default.
• W2051238437 cites W2415725729 @default.
• W2051238437 cites W2469345929 @default.
• W2051238437 cites W2602544133 @default.
• W2051238437 cites W3205607949 @default.
• W2051238437 cites W4246299175 @default.
• W2051238437 cites W7273775 @default.
• W2051238437 doi "https://doi.org/10.1177/107815529600200404" @default.
• W2051238437 hasPublicationYear "1996" @default.
• W2051238437 type Work @default.
• W2051238437 sameAs 2051238437 @default.
• W2051238437 citedByCount "5" @default.
• W2051238437 countsByYear W20512384372022 @default.
• W2051238437 crossrefType "journal-article" @default.
• W2051238437 hasAuthorship W2051238437A5035197851 @default.
• W2051238437 hasConcept C121608353 @default.
• W2051238437 hasConcept C123321153 @default.
• W2051238437 hasConcept C126322002 @default.
• W2051238437 hasConcept C143998085 @default.
• W2051238437 hasConcept C177713679 @default.
• W2051238437 hasConcept C2776694085 @default.
• W2051238437 hasConcept C2778176773 @default.
• W2051238437 hasConcept C2779134260 @default.
• W2051238437 hasConcept C2779268555 @default.
• W2051238437 hasConcept C2780035454 @default.
• W2051238437 hasConcept C2780456651 @default.
• W2051238437 hasConcept C2780962732 @default.
• W2051238437 hasConcept C526805850 @default.
• W2051238437 hasConcept C535046627 @default.
• W2051238437 hasConcept C71924100 @default.
• W2051238437 hasConcept C98274493 @default.
• W2051238437 hasConceptScore W2051238437C121608353 @default.
• W2051238437 hasConceptScore W2051238437C123321153 @default.
• W2051238437 hasConceptScore W2051238437C126322002 @default.
• W2051238437 hasConceptScore W2051238437C143998085 @default.
• W2051238437 hasConceptScore W2051238437C177713679 @default.
• W2051238437 hasConceptScore W2051238437C2776694085 @default.
• W2051238437 hasConceptScore W2051238437C2778176773 @default.
• W2051238437 hasConceptScore W2051238437C2779134260 @default.
• W2051238437 hasConceptScore W2051238437C2779268555 @default.
• W2051238437 hasConceptScore W2051238437C2780035454 @default.
• W2051238437 hasConceptScore W2051238437C2780456651 @default.
• W2051238437 hasConceptScore W2051238437C2780962732 @default.
• W2051238437 hasConceptScore W2051238437C526805850 @default.
• W2051238437 hasConceptScore W2051238437C535046627 @default.
• W2051238437 hasConceptScore W2051238437C71924100 @default.
• W2051238437 hasConceptScore W2051238437C98274493 @default.
• W2051238437 hasIssue "4" @default.

• next